期刊文献+

马铃薯块茎特异性启动子驱动的人白细胞介素-12的遗传转化研究 被引量:2

Genetic Transformation of Human IL-12 Driven by Tuber-specific Promoter from Potato(Solanum tuberosum)
下载PDF
导出
摘要 为获得高效表达人白细胞介素-12(h IL-12)蛋白的转基因马铃薯植株,利用根瘤农杆菌侵染法将前期构建的马铃薯块茎特异性启动子Ppatatin驱动的h IL-12植物表达载体导入马铃薯,通过共培养、筛选、分化等过程获得转基因植株,并结合PCR、RT-PCR、GUS染色及ELISA分析对转基因植株进行鉴定。结果显示,获得12个马铃薯转基因株系,PCR检测表明其中的10个株系目的基因已导入马铃薯基因组,转基因阳性率为83%;RT-PCR分析表明其中的7个株系外源基因在转录水平成功获得表达,ELISA分析表明其中的5个株系有明显的蛋白水平表达。对这7个株系后代的检测表明外源基因成功表达且具有良好的遗传稳定性。 To obtain transgenic potato plants that express human interleukin 12(h IL-12)protein,the early-constructed plant expression vector driven by Ppatatin of potato tuber-specific promotor was transformed into potato by Agrobacterium-mediated transfection,followed by co-cultivation,screening and differentiation,and the transgenic plants were acquired. Techniques of PCR,RT-PCR,GUS staining,and ELISA analysis were performed for the identification of transgenic plants. The results showed that 12 transgenic lines were obtained,and in the 10 transgenic lines the target gene was in the potato genome,i.e.,positive rate was 83%. RT-PCR analysis illustrated that exogenous genes expressed successfully in 7 transgenic lines at m RNA level,moreover,ELISA data showed that 5 transgenic lines presented the high level of h IL-12 protein expression. In addition,the expression of h IL-12 was genetically stable in these 7 transgenic potato lines.
出处 《生物技术通报》 CAS CSCD 北大核心 2016年第5期220-225,共6页 Biotechnology Bulletin
基金 贵州省科学技术基金项目(黔科合J字[2013]2324) 遵义医学院博士启动基金项目(F-587)
关键词 Ppatatin启动子 人白细胞介素-12 转基因马铃薯 植物生物反应器 promoter Ppatatin human IL-12 transgenic potato plant bioreactor
  • 相关文献

参考文献28

  • 1Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plato- produced recombinant pharmaceuticals : vaccines, antibodies and beyond [ J ]. Hum Vacein, 2011, 7 ( 3 ) : 313-321.
  • 2Hefferon K. Plant-derived pharmaceuticals for the developing world [ J ] . Biotechnol J, 2013, 8 ( 10 ) : 1193-1202.
  • 3Mason H S, Herbst-Kralovetz MM. Plant-derived antigens as mucosal vaccines [ J ] . Curr Top Microbiol Immunol, 2012, 354 : 101-120.
  • 4Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications [ J ] Int J Mol Sci, 2010, 11 ( 3 ): 789-806.
  • 5Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease [ J ] . Cytokine Growth Factor Rev, 2014, 25 ( 4 ) : 415- 421.
  • 6Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity [ J ] . Nat Rev Immunol, 2003, 3 ( 2 ) : 133- 146.
  • 7Sabalza M, Christou P, Capell T. Recombinant plant-derived pharmaceutical proteins : current technical and economic bottlenecks [ J ] . Biotechnol Lett, 2014, 36 ( 12 ) : 2367-2379.
  • 8Twyman RM, Schillberg S, Fischer R. Optimizing the yield of recombinant pharmaceutical proteins in plants [ J ] . Curt Pharm Des, 2013, 19 ( 31 ) : 5486-5494.
  • 9Park Y, Cheong H. Expression and production of recombinant human interleukin-2 in potato plants [ J ]- Protein Expr Purif, 2002, 25 ( 1 ): 160-165.
  • 10杨加伟,李伟,葛正龙.马铃薯块茎特异性启动子克隆及其驱动的hIL12表达载体构建[J].遵义医学院学报,2014,37(4):387-392. 被引量:7

二级参考文献69

共引文献57

同被引文献36

  • 1Hamza T, Barnett J B, Li B. Interleukin 12 a key immu- noregulatory cytokine in infection applications [ J ]. Int J Mol Sci, 2010, 11(3) : 789 -806.
  • 2Yao L, Pike S E, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin - 12[J]. Blood, 2000, 96(5) : 1900 - 1905.
  • 3Palendira U, Kamath A T, Feng C G, ct al. Coexpression of interleukin - 12 chains by a self - splicing vector in- creases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobac- terium tuberculosis [ J]. Infect Immun, 2002, 70 (4) : 1949 - 1956.
  • 4Yang J W, Fu J X, Li J, et al. A novel co - immunopre- cipitation protocol based on protoplasttransient gene ex- pression for studying protein - proteininteractions in rice [J]. Plant Mol Biol Rep, 2014, 32(1): 153 161.
  • 5Magnuson N S, Linzmaier P M, Reeves R, et al. Secre- tion ofbiologically active human interleukin -2 and inter- leukin- 4 fromgenetically modified tobacco cells in sus- pension culture[J]. Protein Expr Purif, 1998, 13 ( 1 ) : 45 - 52.
  • 6Park Y, Cheong H. Expression and production of recom- binant humaninterleukin- 2 in potato plants[J]. Protein Expr Purif, 2002, 25(1 ) : 160 -165.
  • 7Bortesi L, Rossato M, Schuster F, et al. Viral and mu- rine interleukin - 10 are correctly processed and retain their biological activity when produced in tobacco [ J]. BMC Biotechnol, 2009, 19(9) : 22.
  • 8Daniell H, Singh N D, Mason H, et al. Plant -made vaccine antigens and biopharmaceuticals [ J ]. Trends Plant Sci, 2009, 14(12): 669-679.
  • 9Lico C, Santi L, Twyman R M, et al. The use of plants for the production of therapeutic human peptides [ J ]. Plant Cell Rep, 2012, 31(3) : 439 -451.
  • 10Yusibov V, Streatfield S J, Kushnir N. Clinical develop- ment of plantproducedrecombinant pharmaceuticals : vac-cines, antibodies andbeyond[ J]. Hum Vaccin, 2011,7 (3) : 313 -321.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部